Cargando…

Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review

Background: This study investigated the effectiveness and safety of switching from Basalin® to Lantus® in Chinese patients with diabetes mellitus (DM). Methods: A retrospective chart review conducted using the electronic medical records of patients hospitalized at the Qingdao Endocrine and Diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xia, Zhang, Lei, Dong, Yanhu, Dong, Chao, Jiang, Jikang, Gao, Weiguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941245/ https://www.ncbi.nlm.nih.gov/pubmed/29862021 http://dx.doi.org/10.12688/f1000research.13923.1

Ejemplares similares

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring
por: Wang, Huiying, et al.
Publicado: (2021)

A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus
por: Hu, Xia, et al.
Publicado: (2019)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus(®) in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
por: Wang, Yiya, et al.
Publicado: (2022)

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open‐label, controlled trial
por: Feng, Wenhuan, et al.
Publicado: (2021)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Lilly Insulin Glargine Versus Lantus(®) in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study
por: Mohan, Viswanathan, et al.
Publicado: (2019)

Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
por: AlRuthia, Yazed, et al.
Publicado: (2022)

Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
por: Bu, Shi, et al.
Publicado: (2017)

Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus(®)): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
por: Yan, Xiang, et al.
Publicado: (2022)

Lilly Insulin Glargine Versus Lantus(®) in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
por: Pollom, Robyn K., et al.
Publicado: (2019)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus(®) Insulin Glargine
por: Ilag, Liza L., et al.
Publicado: (2017)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine
por: Goyal, Parag, et al.
Publicado: (2021)

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus(®) Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
por: Nishiyama, Hiroshi, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus
por: Heise, Tim, et al.
Publicado: (2019)

Basalin is an evolutionarily unconstrained protein revealed via a conserved role in flagellum basal plate function
por: Dean, Samuel, et al.
Publicado: (2019)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
por: Mansell, Kerry, et al.
Publicado: (2019)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
por: Mansell, Kerry, et al.
Publicado: (2019)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
por: Garg, Satish K., et al.
Publicado: (2020)

MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study
por: Derwahl, Karl-Michael, et al.
Publicado: (2018)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey
por: Chapman, Stephen R, et al.
Publicado: (2017)

A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
por: Liu, Min, et al.
Publicado: (2016)

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies
por: Sun, Bin, et al.
Publicado: (2021)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
por: Eledrisi, Mohsen, et al.
Publicado: (2018)

Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pgo2n945ss2e2l9k3b7b7p1v47